Suppliers and packagers for ZYKADIA

ZYKADIA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225	NDA	Novartis Pharmaceuticals Corporation	0078-0694-48	21 TABLET, FILM COATED in 1 BOTTLE (0078-0694-48)	2019-03-18
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225	NDA	Novartis Pharmaceuticals Corporation	0078-0694-84	84 TABLET, FILM COATED in 1 BOTTLE (0078-0694-84)	2019-03-18

Suppliers for the Pharmaceutical Drug: ZYKADIA

Last updated: August 2, 2025

Introduction

ZYKADIA (ceritinib) is an oral targeted therapy developed by Novartis for treating ALK-positive non-small cell lung cancer (NSCLC), particularly in patients who have progressed on or are intolerant to crizotinib. As a critical medication in oncology, its supply chain dynamics are pivotal for healthcare providers, distributors, and stakeholders involved in cancer treatment regimes. This report explores the landscape of suppliers involved in the manufacturing, sourcing, and distribution of ZYKADIA, with a focus on pharmaceutical manufacturing, raw material sourcing, and distribution channels.

Manufacturing Overview

Novartis, headquartered in Switzerland, holds the patent and manufacturing rights for ZYKADIA. The company’s global manufacturing network, primarily situated across Europe, Asia, and the Americas, ensures the drug's production aligns with strict regulatory standards and quality controls. The core manufacturing facilities responsible for ZYKADIA’s production include:

• Novartis' European Manufacturing Sites
  Located in Switzerland and other European countries, these facilities utilize advanced pharmaceutical synthesis and formulation technology to produce active pharmaceutical ingredients (APIs) and the final drug product.

• Asian Manufacturing Units
  Novartis operates manufacturing units in countries such as India and Japan, leveraging regional expertise and cost efficiencies to meet global demand.

Raw Material and API Suppliers

Ceritinib’s manufacturing hinges on high-quality raw materials and active pharmaceutical ingredients (APIs). While Novartis maintains stringent control over its supply chain, it sources certain key raw materials from specialized suppliers worldwide. It is common practice for pharmaceutical companies to establish multiple sourcing channels to mitigate risk and ensure continuity of supply.

• Active Pharmaceutical Ingredient (API) Suppliers
  The API, ceritinib, is synthesized via complex chemical processes that require specialized reagents and intermediates. While Novartis has internal capabilities, some intermediates or certain raw materials may be procured from external suppliers in regions like China, India, or Europe, known for bulk chemical manufacturing.

• Key Raw Materials
  These include various solvents, catalysts, and reagents necessary for chemical synthesis. Suppliers of such materials often include multinational chemical companies with Good Manufacturing Practice (GMP) certifications.

Notable Suppliers:
Due to confidentiality agreements and supply chain protections, specific raw material suppliers are not publicly disclosed. However, industry reports suggest that global chemical suppliers such as BASF, Lonza, and Evonik are typical providers of pharmaceutical-grade intermediates and reagents for high-value oncology drugs.

Distribution and Logistics

Once manufactured, ZYKADIA’s distribution involves a multilayered network incorporating wholesalers, distributors, and specialty pharmacies. The logistics are managed to uphold drug stability, secure handling, and regulatory compliance across different countries.

• Authorized Distributors
  Novartis collaborates with global distribution entities such as AmerisourceBergen, McKesson, and Cardinal Health for North America; Alliance Healthcare and SYNLAB in Europe; and regional local distributors in Asia-Pacific.

• Supply Chain Integrity
  Ensuring the integrity of the supply chain, especially for an oncology agent like ceritinib, involves temperature-controlled logistics, serialization, and real-time tracking to prevent counterfeiting and ensure product efficacy.

Regulatory and Patent Landscape

The supply chain also interacts with regulatory approvals across jurisdictions. ZYKADIA holds approvals from major agencies such as the FDA, EMA, and PMDA, which impose rigorous manufacturing and quality standards. Patents held by Novartis protect the formulation and synthesis process, although generic competition may influence supply dynamics upon patent expiration.

Emerging Trends and Risks

• Generic Competition
  Once patents lapse, multiple generic manufacturers might enter the market, altering supplier dynamics and potentially affecting supply stability and pricing.

• Supply Chain Disruptions
  Global events such as the COVID-19 pandemic, geopolitical tensions, and raw material shortages can impact manufacturing capacity and lead to delays. Diversifying supplier bases and regional manufacturing hubs are strategic mitigations.

• Sustainable Sourcing & Quality Assurance
  Increasing regulatory scrutiny emphasizes sustainable and ethically sourced raw materials, impacting supplier choices and contractual agreements.

Conclusion

The supply chain for ZYKADIA is complex, involving multiple tiers from raw material procurement to final distribution. While Novartis maintains control over manufacturing and Quality Assurance, it engages a network of trusted raw material suppliers and logistics partners to meet global demand for ceritinib. Future considerations include navigating patent expiration, ensuring supply chain robustness, and aligning with evolving regulatory and sustainability standards.

---

Key Takeaways

• Manufacturing is centralized in Novartis’s regional facilities with reliance on global chemical suppliers for raw materials.
• Major distribution partnerships ensure global access but are sensitive to geopolitical and logistical risks.
• Patent expiration will likely diversify supplier sources with potential for generic competitors.
• Supply chain resilience depends heavily on diversified sourcing and logistics management, especially amid global disruptions.
• Quality and regulatory compliance remain critical, influencing supplier selection and operational standards.

---

Frequently Asked Questions (FAQs)

1. Who are the primary manufacturers of ZYKADIA?
Novartis manages the primary manufacturing of ZYKADIA across its facilities in Europe and Asia, employing both internal production and verified external suppliers for certain raw materials.

2. Are there alternative suppliers for ceritinib’s raw materials?
While specific suppliers are confidential, the chemical intermediates used in ceritinib synthesis are typically sourced from multinational chemical companies like BASF, Lonza, and Evonik, which adhere to GMP standards.

3. How does Novartis ensure the quality of raw materials?
Through rigorous supplier qualification, batch testing, and adherence to international GMP standards, Novartis maintains strict quality controls over all raw materials used in ZYKADIA production.

4. Will generic versions of ceritinib affect supply?
Post-patent expiry, generic manufacturers are likely to enter the market, which could impact supply dynamics, pricing, and supplier diversity.

5. What are the risks to the supply chain of ZYKADIA?
Potential risks include raw material shortages, manufacturing disruptions, geopolitical tensions, and logistics challenges—necessitating proactive risk mitigation through diversification and strategic planning.

---

Sources:

[1] Novartis official product information for ZYKADIA.
[2] Industry reports on global pharmaceutical raw material suppliers.
[3] Regulatory agency databases (FDA, EMA, PMDA).
[4] Supply chain analyses from pharmaceutical industry publications.
[5] Market intelligence on patent expiries and generic competition.